Daily Archives: July 19, 2023

A handful of entities are in various stages of the FDA approval process for MDMA and psilocybin drugs (seehereandhere for some of our prior analysis of the issues). FDA approval could happen in the next few years.

But theres a catch: psilocybin and MDMA are both schedule I drugs under the Controlled Substances Act (CSA). And schedule I narcotics are essentially off limits for prescription. So, how will this new system work?

In order for physicians and medical professionals to prescribe and administer FDA approved MDMA and psilocybin formulations, the federal government has to reschedule them. One question I get frequently is whether this would mean a categorical rescheduling of MDMA and psilocybin. In other words, would the government move psilocybin and MDMA, as a whole, to a lower schedule.

The answer to this question is almost certainly no. In all likelihood, the federal government will reschedule the FDA approved drug formulations and leave MDMA and psilocybin on schedule I. There is precedent for this. Gamma-hydroxybutyric acid (or GHB) is a schedule I depressant under the CSA. Drug manufacturers have gotten FDA approval for drugs that contain formulations of GHB for example, XYWAV, and according to that link:

XYWAV is a Schedule III controlled substance. The active moiety of XYWAV is oxybate, also known as gamma-hydroxybutyrate (GHB), a Schedule I controlled substance. Abuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death. The rapid onset of sedation, coupled with the amnestic features of GHB particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (eg, assault victim). Physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely.

Indeed, if you take a look at the DEAs CSA regulations, youll see right there under schedule III: Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act. Translated into English: if a drug containing GHB gets FDA approval, it is a schedule III drug.

All signs point to something similar happening for both MDMA and psilocybin. Theres virtually no way the federal government will loosen up CSA restrictions for non-approved formulations, so well likely see carveouts for those FDA approved drugs on schedule II or III. That will allow a regulated medical market while giving the DEA wide enforcement powers for everyone else.

I should also point out here that the expected rescheduling wont effect the service center market in places like Oregon or Colorado. Those service centers will use psilocybin produced in state-regulated manners, not FDA approved formulations. So none of the benefits of, say, moving a drug to schedule III and getting rid of 280E risks, are going to happen.

Make sure to stay tuned to the Psychedelics Law Blogfor more updates on the psychedelics industry.

Original post:

Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken

The journey itself is only one part of the psychedelic experience. But while many people are now recognizing the need for integrationprocessing, interpreting and incorporating what happened during your tripfewer are focused on what happens before it starts.

Preparation is just as crucial as integration, if not more so, believes Rosalind McAlpine, a PhD candidate at University College London. Most studies and trials include a preparation stage, but there are no established standards for what that entails, and the people designing and leading research often dont have firsthand experience. Its why she helped create the first Psychedelic Preparedness Scale (PPS): Based on feedback from people who actually use psychedelics, it measures the degree to which a person is prepared for a trip.

In societies where plant medicine is part of everyday life, many aspects of what we might call preparedness are often woven into the fabric of the culture, and the community itself acts as a container, McAlpine told Filter. But in the Global North, this is a relatively new construct [and] theres an active need to make time and space for adequate preparation.

Anything we can do before going in to increase the likelihood of having a safe, meaningful and potentially transformative experience should be exposed.

In a presentation at Breaking Convention 2023, she likened it to a day trip to Paris: You dont have to pack, research, or plan a route; youll still have an experience. But youll probably end up missing a lot of what you hoped to encounter, and you might even end up in an unsafe situation.

Psychedelics, too, will bring you an experience no matter whatbut without familiarizing yourself with the possibilities, you could not only miss the benefits, but potentially suffer real harms.

Challenging experiences are often the most transformative parts of psychedelic journeys, but these can be incredibly intense: from encounters with death or otherworldly entities, to repressed memories resurfacing. People need tools to navigate these moments when they arise.

Blogs and articles provide blanket advice; retreat centers give attendees guidelines; but none of this is standardized or geared toward the clinical setting, and little of what users and practitioners are doing is documented, McAlpine said.

The PPS aims to change that. From the perspective of harm reduction, she said, anything we can do before going in to increase the likelihood of having a safe, meaningful and potentially transformative experience, reducing the risks involved and potentiating challenging experiences as growth opportunities rather than traumatic events should be exposed.

The team gathered items for the scale based on feedback from both learned experience experts and lived experience experts.

McAlpines team defines psychedelic preparedness as a state preceding the session that is conducive to a safe and personally meaningful experience. The state will allow the participant to be psychologically, physically, and socially ready for the content and consequences of the experience, and will most likely involve a variety of extra-pharmacological factors.

The team gathered items for the scale based on feedback from both learned experience experts in psychiatry, philosophy and psychedelic research and, uniquely, lived experience experts undergoing psychedelic healing, whose perspective is often missing from scientific literature.

The intention was to include patient and public involvement [or PPI], throughout the whole process, McAlpine said, from creating the scale to implementing and optimizing it, in order to reflect not only the rigorous, hard-science framework, but also the voices of those people who would most benefit. PPI aims to bring accountability, transparency, and relevance to scientific studiesdefined by the authors of a paper that inspired the team as research performed with or by patients and members of the public, rather than to, about, or for them.

The scale was built in a three-study process. This involved collecting feedback through focus groups and interviews to determine which measures should be included; exploratory and confirmatory factor analyses to gauge which measures most impacted preparedness; and preliminary implementation. The scale was then validated by two online samples of psychedelics users (516 and 716 people, respectively), and tested on 46 people attending psilocybin retreats at partnering centers, tracking preparedness levels and outcomes.

Preparedness elements defined by the PPS fall into four categories. These include knowledge expectations, meaning the person had an understanding of the substance itself and what the experience might be like; support and planning, meaning they felt the substance was safe to take and had a supportive physical environment; and psychophysical readiness, or being prepared for the whole range of emotional experiences, from bliss to horror, as well as physical possibilities, like vomiting or urination.

Across the board, participants with higher levels of preparedness had significantly better outcomes than those with lower levels.

The final category was intention preparation, involving measures like journaling, breathwork, and meditationrated most important by participants. McAlpines team plans to pilot a meditation-based preparedness intervention at UCL.

Through meditation, one participant said, I was able to enter the psychedelic state with a more open and receptive mindset. It helped me shed some of my preconceptions and allow the experience to unfold organically, without trying to control it or impose my own expectations.

Another noted, [Meditation] allowed me to approach the experience with a sense of curiosity and exploration, rather than fear or resistance.

Measures of participants outcomes included emotional breakthrough; mystical experience; challenging experience; post-psychedelic growth; the centrality of the event (whether, and how, the experience became central to their identity and a turning or reference point for their life story); wellbeing; relationship attachment style; extraversion; altered states of consciousness (gauging the acute experience); and depression, anxiety, and stress.

The scale doesnt prevent difficult things from happening, but it can point you in the right direction to reduce harm and maximize benefit.

Across the board, participants with higher levels of preparedness had significantly better outcomes than those with lower levels. High preparers had higher scores on positive measures such as unity, spiritual experience, blissful state, and insightfulness than low preparers; they also showed significantly greater reductions in depression, anxiety, and stress. When high preparers did have challenging moments in a trip, they were more likely to turn them into growth opportunities, and they were also more likely to experience positive changes in wellbeing after the experience.

The scale doesnt prevent difficult things from happening, but it can point you in the right direction to reduce harm and maximize benefit, McAlpine said. If one went into those experiences with no idea that was going to happen, it can be an unnecessary challenge Even a little bit of psychoeducation [and] expectation management can go incredibly far.

The PPS could serve as a valuable screening tool to identify individuals who may require additional preparation or support prior to undergoing psychedelic interventions, thereby functioning as a pre-intervention assessment to pinpoint areas of preparedness that necessitate attention, the researchers wrote. Furthermore, the PPS could serve as an outcome measure to evaluate the effectiveness of psychedelic preparedness interventions or to compare the efficacy of different preparation protocols.

Just because a study is conducted in a scientific setting doesnt mean its safe, as evidenced by allegations of abuse and misconduct in some of the MDMA trials conducted by MAPS. There needs to be more investigation and reporting of whats going on in those preparation sessions, specifically within the context of clinical psychedelic-assisted psychotherapy, McAlpine said.

While the PPS was co-created with people who use psychedelics, the studies behind it focused on clinical settings, limiting researchers to including only people who could legally disclose their psychedelic usethose who had participated in research studies, clinical trials, or retreats. (Only clinical-trial participants contributed to the creation of the scale items.)

The last thing we want is to be like, Were the scientists, were right.

Obviously, this misses a massive swath of the user base, as McAlpine lamented, and vastly underrepresents the Indigenous people who are the original keepers of the largest body of knowledge on the subject. It also impacts the demographic makeup of their samples: The academic contributors, unsurprisingly, were predominantly white men. The lived-experience experts were more diverse by gender and nationality (data on sexual and gender identity were not collected). But respondents were still largely white, educated and well-off, hailing from the United Kingdom (mostly) and other European countries.

The PPS is open-access, and McAlpine encourages everyone to use it. She now calls upon others to pick up where her teams research left off, capturing a broader scope of lived experience. The scale is currently being used in a DMT neuroimaging study at University College London, and organizations such as the Institute of Psychedelic Therapy have used it for therapist training.

The aim is to keep it iterative and intuitive, learning from as many sources as possible to shed light on what works and what doesnt, McAlpine said, [while] giving voice to people who dont always get it. The last thing we want is to be like, Were the scientists, were right.

Image via PxFuel

More here:

The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter

As interest in psychedelic substances grows, ensuring the safety and purity of these substances is an increasingly important thing to practice. One of the most effective ways to mitigate risks associated with drug use is through the use of testing kits. Organizations like DanceSafe.org offer testing kits that allow individuals to analyze the composition of various psychedelic drugs, helping identify potential adulterants or contaminants.

Before delving into the specifics of testing various psychedelic drugs, it is essential to comprehend the purpose and benefits of testing kits. These kits are designed to provide users with crucial information about the contents of a particular substance. By analyzing the presence of adulterants, such as harmful chemicals or other drugs, testing kits help individuals make informed decisions and reduce the risks associated with substance use.

Testing your psychedelics is very easy and only takes 5 minutes. You should never skip testing your psychedelics, specially if buying from strangers or new dealers. Even if you have a reputable seller, always test your drugs, as you never know if their supply has changed.

If you are afraid that testing your drugs will be expensive, fear not. Testing kits are affordable. The LSD and ketamine kits are only $20 each, while the MDMA one is $50 (since it includes 3 reagents). Plus, each kit can perform between 50-75 tests. That should be enough to last you a long while.

To begin testing a psychedelic substance for adulterants, it is important to choose a suitable testing kit. DanceSafe.org is a reputable organization that offers a range of testing kits specifically designed for different types of substances which has become drug users favorite go-to brand. Their kits often utilize reagent tests, which involve adding small amounts of the substance being tested to a reagent chemical and observing color reactions to determine its composition. Additionally, DanceSafe.org provides detailed instructions and resources on how to use their testing kits effectively. (This is not a sponsored post. They are just the most popular, affordable testing kit manufacturer).

There are different types of reagent tests that can be utilized for testing a variety of drugs. The common reagent tests you can find are: Marquis, Simons, Froehde, Liebermann, Morris, Ehrlichs, Mandelin, Mecke, and Folin. Lets break down what the purpose of each is. Each link will take you to the corresponding kit page on DanceSafe.

Marquis: The Marquis reagent is a reagent that is used to test for the purity of MDMA and cocaine. It effectively reacts with amphetamines. The Marquis reagent cannot be used alone and should be with at least another reagent to confirm the purity of a substance. It is the first step in testing MDMA and second step in testing cocaine.

Simons: This is a secondary test that is almost always used alongside another reagent for confirmation. It is one of the three reagents used to test MDMA. Simons helps differentiate between MDMA and MDA, as well as methamphetamine and amphetamine.

Froehde: This is a reagent also used in testing MDMA but can produce unique color reactions with substances such as 2C-B, mescaline, and some cathinones.

Liebermann: This reagent is helpful for identifying possible cocaine adulterants like levamisole. It is also useful for testing substances like amphetamines, ketamine, and more unusual drugs.

Morris: This testing kit that can distinguish ketamine from DCK, 2-FDCK, and other novel dissociatives. It can also be used to determine the presence of cocaine.

Ehrlichs: This reagent is used to test the purity of LSD to ensure it is not adulterated with substances like 25I-NBOMe.

Mandelin: The Mandelin reagent is used as an additional layer of testing for a variety of drugs. This test provides more information when other reagents do not go as expected. It can react with amphetamines, certain cathinones, cocaine, ketamine, 2C-B, 2C-I, mescaline, PMA, PMMA, oxycodone, heroin, aspirin, and sugar.

Mecke: Similar to the Mandelin reagent, the Mecke test is used to perform more specialized and complete testing. It can help confirm the identity of substances such as entactogens, cathinones, 2C-B, 2C-I, mescaline, oxycodone, heroin, and sugar.

Folin: This last reagent is useful for detecting a class of drugs called piperazines, which include BZP and TFMPP.

LSD is commonly sold on blotter paper or in liquid form. To test LSD for adulterants, carefully cut a small portion of the blotter or gel tab and place it on a white, ceramic plate. It is important that it is white, as it will facilitate seeing the color.

Candies, purple- or blue-dyed blotters, and gel tabs can be difficult to test. Although sometimes possible, the reaction can be hard to read. Gel tabs may take longer to dissolve.

Hold the reagent bottle an inch or two above the sample and squeeze one drop of Ehrlichs reagent, and observe the color reaction over the next five minutes. A violet hue indicates the presence of LSD. Once you observe the color reaction, dispose of the small piece of the blotter. Do not consume a tested blotter. Consuming Ehrlichs reagent can be fatal.

If Ehrlichs doesnt turn purple, you definitely do not have LSD. Drugs like 25I-NBOMe do not react with Ehrlich, so it is possible the LSD sample is adulterated. Do not consume an adulterated LSD tab.

If Ehrlichs turns purple, there is a high chance you have LSD. It may be reacting with another indole, but you are not getting an immediate red flag that something is wrong.

LSD will show up purple on an Ehrlich's reagent test. No reaction indicates an adulterated substance. Source: DanceSafe

MDMA is often found in pill or powdered form. To test MDMA, you will require three different reagents: Marquis, Simons, and Froedhe. All three are required for a comprehensive analysis of the sample. To test MDMA, scrape a small amount of the pill or powder onto a testing plate. You will need enough for three different reactions.

Place a drop of the marquis reagent on your MDMA sample. In the presence of MDMA, Marquis will quickly turn black, or you will see purple at first.

This step will help you differentiate between MDMA and MDA. Simons turns blue in the presence of MDMA and will not react or turn a dark grey with a hint of green in the presence of MDA. Place a drop on another clean sample.

Lastly, this step will help test for the very rare occasion that you were sold drugs called APBs under the guise of MDMA. This reagent is most useful for testing something that was sold to to you as an APB. It can be hard to differentiate between an MDMA/MDA reaction and an APB reaction, so do not assume you have an APB reaction unless theres very, very clear purple in it. Pleace a drop on another clean sample. Do not test on previously tested samples.

Ketamine has risen in popularity in the past couple of years, especially in the club, rave, and gay scenes. With more demand for ketamine, there is the possibility of manufacturers cutting corners and adulterating it to reduce costs. There are an increasing number of drugs that are being sold under the guise of ketamine presently, and these can include ketamine analogs, PCP analogs, novel dissociatives. Because ketamine is often sold in a white powder form, it is also possible it can be adulterated with cocaine or fentanyl. To test for ketamine, Morris reagent is used. Other tests can be used to further analyze the drug such as those testing for cocaine or fentanyl. The Morris reagent is a two-part process that comes in two bottles: a pink one (Morris A) and a green one (Morris B)

Use at least 5-10mg of material to get an accurate reading. On a white ceramic plate, put a drop of the pink bottle (Morris A) that comes with the Morris testing kit onto your sample.

Put a drop of the green bottle (Morris B) on the same sample. The sample should have both Morris A and Morris B on it.

Using a toothpick or the sharp point of a knife, stir the mixture for a full 30 seconds.

A ketamine sample will turn purple. Cocaine will turn bright blue, like a Jolly Rancher. DCK or 2F-DCK will turn dark blue/gray. Most other drugs will turn a dull green, meaning a negative reaction.

It is important to learn how to read a ketamine test to be sure of the authenticity of your substance. Source: DanceSafe

While shrooms do containe indole groups, Ehrlichs reagent is not recommended to be used with them, as it is only meant to test LSD. There are no current reagents that test shrooms for adulterants.

The most important harm reduction practice is triple checking that you actually bought psychedelic mushrooms and are not being sold poisonous mushrooms.

If you personally harvested mushrooms in the wild, it is very important to get them identified by a professional mycologist group, forum, individual, or association especially if you do not have much experience with foraging wild mushrooms. Galerina is a genus of mushrooms that are commonly misidentified as shrooms; this genus contains some extremely poisonous species. Identifying mushrooms is not as easy as one may think, so only do so, if you are 100% sure of your skills. Ingesting a wrongly-identified mushroom can lead to serious health consequences or death.

If you are growing mushrooms at home, ensure that the spore vendor where you bought your spores from is reputable. Do your due diligence and ask around psychedelic communities for their opinion on a vendor you are thinking of using, as many people may have had experiences with them or know of a better vendor.

Although rare, there have been instances where fentanyl has been found in certain psychedelics, such as ketamine. While there are no testing strips on the market that can detect every fentanyl analog, using a strip is still good practice to detect the presence of any analog. You can test for fentanyl on any LSD, MDMA, ketamine, cocaine, pharmaceuticals, and more.

To test for fentanyl in a sample, simply dilute a sample of the drug in water. The ratio of powder to water is 10mg / ml. Dip the testing strip in. If the testing strip has two red lines, it has no fentanyl. If it has one red line, it has fentanyl.

Do not skip on testing your substances. Responsible drug use requires testing substances every time before consuming them. Always test your drugs, even if you bought them from the same seller multiple times in the past without problems. Drug dealers may change the distributor where they get their drugs from, or may be unaware where they come from. Some drug dealers test your drugs for you and show you the results of the reagent tests before selling them, but this is not common practice.

In public spaces like concerts and festivals, it is more common for people to take drugs without testing them. It is good practice to bring a testing kit with you it only takes 5 minutes of your time. Some festivals also bring harm reduction and testing organizations to their grounds to help festival goers test their drugs, and no, the police will not get you because you use them. These organizations are there to help you.

It is also common for harm reduction organizations to exist in your city. It is more than likely that someone in your city has started a harm reduction service. There are syringe exchange programs, mobile harm reduction testing sites, and harm reduction hotlines that are available to you to test your drugs, in the case you do not want to do it yourself at home.

Do not feel pressured to take drugs you arent sure of, and always suggest testing them. Doing so helps break down stigma surrounding drug testing, too. And do not fall victim to the mindset of oh, but Im wasting product by testing. Only a minimal amount is required to test a drug, and it is better off losing milligrams of your product than losing function of your body or even losing your life.

It is crucial to remember that testing kits provide preliminary information and are not infallible. While reagent tests can detect the presence of specific substances, they cannot identify all potential contaminants. Additionally, different adulterants may produce similar color reactions, requiring further testing or professional lab analysis for confirmation. Therefore, if there is any uncertainty about the results, it is advisable to err on the side of caution and refrain from consuming the substance.

Testing kits provided by organizations like DanceSafe.org play a vital role in promoting personal safety and harm reduction within the realm of psychedelic drug use. By utilizing these kits and following proper testing procedures, individuals can gain valuable insights into the composition of their substances, helping them make informed decisions about their own well-being. Part of being a person who uses drugs is responsibly doing said drugs. It is crucial to prioritize personal safety, education, and responsible drug use practices to minimize potential risks associated with psychedelic substances.

Psychedelic Spotlight's Bonfire division offers aFREE Psychedelics for Beginners coursewhere you can learn everything about the different psychedelic compounds, the importance of mindset, how to prepare for your psychedelic experience and how to integrate it.

Disclaimer: Psychedelic Spotlight does not condone the use of illegal substances. The purpose of this article is for educational and harm reduction purposes only. If you suffer from a medical or mental condition, please consult with your doctor before taking any substance.

See more here:

How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight

PROVIDENCE, R.I., July 18, 2023 (GLOBE NEWSWIRE) -- Cannabis Science Conference (CSC), the premier cannabis science conference focusing on analytical science, medical cannabis, cultivation and psychedelics, announced today that its fall edition will make its first-ever appearance in Providence, R.I. Taking place at the Rhode Island Convention Center from September 2022, this highly anticipated conference will become the epicenter for education related to the exciting cannabis and psychedelic markets.

We are thrilled to bring the Cannabis Science Conference to Providence, said Megan LHeureux, group editorial director of Cannabis Science and Technology and Cannabis Patient Care magazines. Rhode Island is emerging as a major player in the cannabis science industry, and this event will serve as a dynamic hub for professionals to learn, network and collaborate.

Keynote speaker Dr. Peter Grinspoon, a primary care doctor at Massachusetts General Hospital, instructor in medicine at Harvard Medical School, and 25-year cannabis specialist, will share his knowledge in an address titled, Cannabis Reconsidered: A Science-Based Look at the True Harms and Benefits. In a recent interview with Cannabis Science and Technology, Grinspoon discussed what he hoped attendees will learn from this presentation. We all need to be humble. We all need to forget what we think we know about cannabis. Nobody, including me, has a monopoly on the truth. We just have to think for ourselves, said Dr. Grinspoon. I'm just really hoping that by challenging some of the myths, methodology, and misconceptions that people will come away feeling more confident in thinking for themselves on this issue.

Dr. Dustin Sulak, a distinguished integrative medicine physician, will also take the stage at the fall event for a keynote address. With a deep-rooted practice in osteopathy, mind-body medicine and medical cannabis applications, Dr. Sulak is renowned for his expertise in the medical use of cannabis. His keynote address, The Knowledge and Art of Combining Cannabinoids for Treatment Success, will explore recent advancements in accessing rare cannabinoids and challenge assumptions about THC and CBD combinations. CSC will also feature several fireside chats with industry experts such as world-renowned cannabis geneticist Adam Jacques as well as a hot button discussion on THC potency inflation with leading analytical scientists.

CSC is designed to provide world-class science education and insights. Attendees can expect expert-led presentations, roundtable discussions, exhibits and a full-day pre-conference workshop called Canna Boot Camp, taking place on September 20. Canna Boot Camp covers a wide range of cannabis science topics, including cultivation, preprocessing, sample preparation, analytical testing, extraction and edibles manufacturing.

The conference boasts dedicated program chairs and an educational steering committee, ensuring the highest quality and relevant content. CSC places great emphasis on networking and collaboration opportunities among attendees, speakers and exhibitors, fostering a vibrant atmosphere for knowledge exchange and business growth within the cannabis industry.

To register and learn more, please visit the registration page.

About Cannabis Science Conference:

Cannabis Science Conference (CSC) is the industrys premier science event, focusing on analytical science, medical cannabis, cultivation and psychedelics. CSC brings together cannabis and psychedelicindustry experts, including instrument manufacturers, testing labs, research scientists, cultivators, medical practitioners, policy makers, patients and interested novices to network and share ideas. CSC runs semiannual events nationwide in emerging markets, aimed at improving cannabis and psychedelic science. Join us for world-class education, stellar networking and the opportunity to connect with thought leaders, leading scientists, pioneers in cutting-edge medical applications and industry suppliers. For more information, visitwww.cannabisscienceconference.com.

Media Contact: Lauren Garafola MJH Life Sciences lgarafola@mjhlifesciences.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0392bfc7-563b-4b86-bd0d-9e70982b71a3

Link:

Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire

Good morning and welcome to the A.M. Alert!

RIVAS SAYS YES TO THREE CONTROVERSIAL BILLS

Via Mathew Miranda

Speaker of the Assembly Robert Rivas supports legalizing psychedelic drugs, raising health care worker minimum wage to $25 and a controversial housing bill opposed by some Assembly Democrats and the San Francisco Giants.

He doled out those opinions, plus more on his leadership plans and priorities for a new era in the California Legislature, at the Sacramento Press Club on Wednesday.

The housing bill, introduced by Sen. Scott Wiener, D-San Francisco, passed the Assembly Committee on Natural Resources despite the chairs opposition on Monday. It extends an existing law that allows streamlining of multifamily housing developments in cities that arent meeting state-mandated requirements.

Im excited to support any and all efforts to ensure that well get a good policy across, Rivas said.

Wiener is also pushing for SB 58 to decriminalize psilocybin (magic mushrooms), psilocyn, DMT, mescaline and ibogaine. The bill passed its final policy committee on Tuesday, and now advances to the Assembly Appropriations Committee. This marks the San Francisco Democrats second bid to remove criminal penalties for possession and personal use of certain psychedelics.

Rivas said yes, when asked if California should legalize psychedelics.

As for the proposed minimum wage increase, Rivas paused for 10 seconds before saying I want to be respectful of the process, yes.

NEWSOM STUMPS FOR MENTAL HEALTH BOND ISSUE

Via Maggie Angst...

With budget negotiations in the rearview mirror, Gov. Gavin Newsom is turning his attention to the next priority -- securing legislative and voter approval of his multi-billion-dollar plan to house thousands of mentally ill people across California.

Newsom held a roundtable Wednesday with state and local lawmakers and behavioral health advocates to drum up support for a proposed ballot measure that he says will help the state treat brain health early before we punish it later.

Story continues

There is no other issue that impacts more people in more ways on more days than the issue of behavioral health, the issue of mental health, Newsom said during a press briefing afterward.

A pair of bills from Sen. Susan Talamantes Eggman, D-Stockton, and Assembly Member Jacqui Irwin, D-Thousand Oaks, that would enact the governors plans are making their way through the legislature.

Irwins calls for using $4.68 billion in new bond revenue to build 10,000 new mental health treatment beds. Eggmans would reform the states Mental Health Services Act, passed by voters as Proposition 63 nearly 20 years ago and used by counties to fund services for residents with serious mental health issues.

Newsoms vision is to combine the two bills into one ballot measure that would go before voters in March 2024. But first, two-thirds of lawmakers need to vote in support.

OPIOID OVERDOSE PREDICTIONS....FOR 2022

Via Gillian Brassil...

It sounds a bit odd to predict something for a year thats come and gone. But thats what the Centers for Disease Control says about opioid deaths nationwide in 2022. They stayed flat, although California is among the states where cases are still expected to have risen.

The data is predictive to adjust for incomplete reporting. Drug overdose deaths are often initially reported without a cause because they require lengthy investigation

The latest report predicts fewer than 110,000 overdose deaths for the year ending in Feb. 2023, with most caused by illicit synthetic drugs like fentanyl. Still, CDC data predicts that California cases will rise year over year by about 200 cases to roughly 12,200 deaths. It is among the half of states predicted to increase rather than decrease.

Overdose deaths had been rapidly increasing since 2019, the onset of the coronavirus pandemic. About 69,000 deaths were suspected for the year ending in Feb. 2019, ballooning to over 110,000 in the year ending in Feb. 2022.

Dr. Rahul Gupta, director of the White House Office of National Drug Control Policy, said the data shows our nation is finally seeing early indications of success in the overdose rate that we must sustain with even more urgent action.

Tackling the opioid epidemic has been a Biden administration priority. This week, the White House announced a plan to curb the spread of a powerful veterinary tranquilizer, xylazine, that is being combined with illicit fentanyl.

Gov. Gavin Newsom too has made cracking down on fentanyl a priority, launching a partnership between the state and San Francisco to seize illicit drugs and approving $30 million for making its own naloxone from settlements with opioid manufacturers.

Naloxone can reduce or reverse effects of an opioid overdose. If you think someone is having an overdose, the California Department of Public Health recommends the following:

Call 911 and give naloxone.

Keep the person awake and breathing.

Lay the person on their side to prevent choking.

Stay with the person until 911 responders arrive.

QUOTE OF THE DAY

The best place for Mexican food in Sacramento? Laurel Rosenhall asked Robert Rivas at the Sacramento Press Club.

(long pause)

Really? Assemblywoman Sharon Quirk-Silvas house he responded.

Best of The Bee:

Original post:

New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News

Welcome to TDRs review of the Top 5 Psychedelic Developments for the week of July 10. Aside from presenting a synopsis of events, we provide market commentary to summarize the week that was for publicly-listed companies.

5. Ketamine For Severe Depression: 1 In 5 Achieve Remission After A Month In Promising Aussie Trial

A month-long course of ketamine injections may be an effective treatment for severe depression, say Australian doctors who found promising remission rates in their largest-of-its-kind trial.

One in five adults in the Ketamine for Adult Depression Study (KADS) achieved total remission from their symptoms after a month of twice-weekly subcutaneous ketamine injections, reported the UNSW Sydneyled team.And nearly a third of the 179 participants in the placebo-controlled trial had a 50% reduction in symptom severity.

However, these benefits disappeared after treatment cessation, which the researchers said suggested a need for longer-term treatment to maintain the antidepressant effects.

4. Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS

Tryp Therapeutics has received confirmation from the U.S. Food and Drug Administration (FDA) that its review of Tryps Investigational New Drug (IND) #163,994 is complete and that the company may proceed with its Phase 2a clinical trial at Massachusetts General Hospital investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome (IBS).

The planned study in collaboration with Massachusetts General Hospital will evaluate the effect of psilocybin-assisted psychotherapy in patients with treatment-resistant IBS who experience chronic abdominal pain and other debilitating gastrointestinal symptoms. Many of these patients also suffer from fibromyalgia, anxiety and fatigue. The primary efficacy endpoint of the study will be improvement in abdominal pain which will be measured at four weeks post the final therapist-monitored psychedelic drug session, along with numerous other secondary endpoints including changes in brain connectivity.

__________

More Than6 in 10American Registered Voters Support Legalizing Regulated Therapeutic Access To Psychedelics35%Indicate Strong Support

__________

3. Psychedelic Stocks Pause, Underperforming Peer Biotech Indices

After a strong double-digit run last week, the psychedelic sector took pause, as reflected by theAdvisorshares Psychedelics ETF (PSIL)0.97%. The performance lagged biopharma peers indices such as theNasdaq Junior Biotechnology Index3.58%andNasdaq Biotechnology Ishares ETF3.18%which both rose moderately. TheNASDAQ 1003.37%andS&P 5002.28%also rebounded on the back of a falling consumer price index print.

Heres how the Health Care (Biotechnology) sector performed:

In the news

Beckley Retreats has extended its strategic partnerships with the Heroic Hearts Project and Imperial College London.

Berkeley, California City Council has approved a resolution todeprioritize the enforcement of laws prohibiting psychedelics.

BetterLife Pharm highlighted the American College of Physicians guidelines for the treatment of Major Depressive Disorder published recently in Annals of Internal Medicine.

Bipartisan congressional lawmakers are celebrating the inclusion of a psychedelics research amendment as part of a must-pass defense bill thats on the House floor.

Bipartisan lawmakers pushed for the adoption of marijuana and psychedelics amendments as part of a large-scale defense bill at a House committee meeting on Tuesdaybut the proposals fate remains uncertain following complications over unrelated measures being pushed by conservative members.

Bright Minds Biosciences announced that, further to its news release on June 22, 2023, the Company will consolidate its common shares on a five (5) to one (1) basis.

CybinInc. has commenced the development of a streamlined, scalable version of its EMBARK Training Program, known as EMBARK.

Denver Post expects psilocybin therapy to come sooner rather than later

Drug Science to launch first study to directly test molecular neuroplasticity effects of DMT in humans.

Lucy Scientific Discovery announced the launch of Twilight a blend of Amanita and Reishi mushrooms that include a variety of other nootropics promoting improved cognitive function and enhanced sleep quality.

Lucy Scientific Discovery has appointed Richard Nanula, former CFO at Amgen Inc. and The Walt Disney Co. as its new CEO.

Massachusetts: Political strategists have quietly filed paperwork to put a therapeutic psychedelics legalization initiative on the states 2024 ballot.

Meme Of The Week

New study by leading academics in the psychedelics space finds that psilocybin combined with therapy could be more cost-effective at treating major depression disorders than currently used methods.

New study reveals distinct effects of excitalopram (Lexapro) and psilocybin on brain responses to emotions, highlighting the unique approaches of these treatments in addressing depression.

Psilocybin dispensary crackdown in Windsor, Ontario.

Psycheceutical Bioscience has dosed the first healthy volunteer in a Phase I trial investigating a topical administration of ketamine for the treatment of post-traumatic stress disorder (PTSD)

PsyenceGroup announced the appointment of Christopher Bull to the board of directors of the Company effective immediately.

Public awareness about psychedelics is growing, but more needs to be done

OUT NOW: The results of the inaugural UC Berkeley Psychedelics Survey

47% of all respondents have heard about psychedelics recently 48% of those respondents associate psychedelics with mental health

Explore the data here: https://t.co/IzPJi2oITl pic.twitter.com/HtWn2k97N4

Rep. Dan Crenshaw again pleaded his case for the advancement of psychedelic use in the mentally ill. The matter at hand pertains to a critical Bill that aimed to utilize and study psychedelic treatments for mental illnesses in conjunction with theDepartment of Defense.

Three people associated with an illegal magic mushroom dispensary in London, Ont. were charged with drug related offences more than a month ago.

UC San Diego Psychedelics and Health Research Initiative received a $1.5 million gift from philanthropist Eugene Jhong to further our understanding of the unique states of consciousness induced by DMT and how it could benefit human health.

West Hollywood will host a free Community Educational Forumabout the possible state-level decriminalization of mushrooms (Psilocybin) and certain hallucinogenic drugs.

2. Majority Of U.S. Voters Support Therapeutic Use Of Psychedelic Drugs

Most U.S. voters support legalizing psychedelics for therapeutic use, and a growing proportion of people who report using psychedelics are microdosing taking tiny amounts of the drugs and using them for therapeutic purposes, according to a survey released Wednesday by the UC Berkeley Center for the Science of Psychedelics.

Sixty-one percent of people say they would support creating a regulated legal framework for the therapeutic use of psychedelics, according to the survey, which polled 1,500 registered voters online and over the phone June 9-15.

A slim majority, 56%, also say they would support federal regulators approving the use of psychedelics for prescription use.

1. California Health Committee Votes 9 To 2 To Legalize Psilocybin, DMT And Ibogaine

A second California Assembly committee has approved a Senate-passed bill to legalize the possession and facilitated use of certain psychedelics, bringing it one step closer to the floor.

Another California Assembly Committee Approves Senate-Passed Psychedelics Legalization: The sponsor said last month that the bill wasup against a challenging road toward passage but has now cleared a major hurdle.https://t.co/6MOvfammnO

The legislation from Sen. Scott Wiener (D) advanced through the Assembly Health Committee in a 9-2 vote on Tuesday. This comes about two weeks after it wasapproved by the Public Safety Committeeand two months after itcleared the full Senate. The measure must now go to the Appropriations Committee before potentially moving to the floor.

Tuesdays vote is a welcome development for advocates, as Wiener said last month that the bill wasup against a challenging road toward passagegiven its referral to the Health Committee, where the chances of approval were less certain.

See more here:

TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report